Skip to main content

Drug Interactions between ruxolitinib topical and voriconazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

voriconazole ruxolitinib topical

Applies to: voriconazole and ruxolitinib topical

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may increase plasma concentrations (Cmax) and systemic exposure (AUC) of topical ruxolitinib, which is primarily metabolized by the isoenzyme. Following administration of ketoconazole (200 mg twice daily for four days), a potent CYP450 3A4 inhibitor, healthy subjects then received a single dose of ruxolitinib (10 mg orally). The Cmax and AUC of ruxolitinib increased 33% and 91% respectively, compared to healthy subjects receiving the oral ruxolitinib dose alone. Increased exposure to ruxolitinib may increase the risk of adverse events. However, clinical data for topical ruxolitinib are not available.

MANAGEMENT: Concomitant use of topical ruxolitinib with potent inhibitors of CYP450 3A4 should generally be avoided. It may be advisable to monitor patients for the development of adverse effects. Consultation with individual package labeling, as well as relevant institutional protocols, may be advisable for further guidance.

References (2)
  1. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation
  2. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation, 2

Drug and food interactions

Major

ruxolitinib topical food

Applies to: ruxolitinib topical

MONITOR CLOSELY: Smoking during treatment with topical ruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies, including lymphomas. During clinical trials, patients who were current or past smokers and received oral Janus Kinase (JAK) inhibitors to treat inflammatory conditions had an additional increased risk of overall malignancies. Additionally, oral JAK inhibitors reportedly increase patients' risk of MACE, including cardiovascular death, myocardial infarction, and stroke, particularly in patients who are current or past smokers or patients with other cardiovascular risk factors.

MANAGEMENT: The potential risks and benefits of topical ruxolitinib should be carefully weighed prior to initiating therapy, particularly in patients with cardiovascular risk factors, as well as those with a history of malignancy, those who develop a malignancy while on treatment, and/or patients who are current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing topical ruxolitinib in patients who have experienced a myocardial infarction or stroke.

References (2)
  1. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation
  2. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation, 2
Moderate

voriconazole food

Applies to: voriconazole

ADJUST DOSING INTERVAL: Food reduces the oral absorption and bioavailability of voriconazole. According to the product labeling, administration of multiple doses of voriconazole with high-fat meals decreased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 34% and 24%, respectively, when the drug is administered as a tablet, and by 58% and 37%, respectively, when administered as the oral suspension.

MANAGEMENT: To ensure maximal oral absorption, voriconazole tablets and oral suspension should be taken at least one hour before or after a meal.

References (2)
  1. (2002) "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals
  2. Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer